Table 2.

Results of in vitro cyclooxygenase and lipoxygenase inhibitory activity.

Name	Concentration	COX-2% inhibition (mean ± SEM)	COX-2 IC50 (μg/ml)	5-LOX % inhibition (mean ± SEM)	5-LOX IC50 (μg/ml)
Hp. Chf	1000	77.40 ± 0.25∗∗∗	33.81	81.73 ± 0.37∗∗∗	26.74
	500	72.41 ± 0.30∗∗		75.27 ± 1.37∗∗∗
	250	65.79 ± 1.28∗∗∗		69.62 ± 0.11∗∗∗
	125	61.32 ± 0.68∗		63.81 ± 0.51∗∗∗
	62.5	56.49 ± 0.73∗∗		59.08 ± 0.12∗∗∗
Hp. EtAc	1000	76.38 ± 0.76∗∗∗	87.56	80.47 ± 0.70∗∗∗	67.51
	500	69.37 ± 0.52∗∗∗		73.57 ± 0.43∗∗∗
	250	62.90 ± 1.16∗∗∗		65.12 ± 0.94∗∗∗
	125	54.48 ± 0.54∗∗∗		57.76 ± 1.09∗∗∗
	62.5	45.56 ± 0.69∗∗∗		49.38 ± 0.50∗∗∗
Hp. Cr	1000	65.94 ± 0.71∗∗∗	200	71.50 ± 0.56∗∗∗	106.99
	500	58.28 ± 0.54∗∗∗		65.40 ± 0.55∗∗∗
	250	52.65 ± 0.91∗∗∗		59.36 ± 0.57∗∗∗
	125	45.30 ± 0.55∗∗∗		51.30 ± 0.52∗∗∗
	62.5	37.63 ± 0.98∗∗∗		44.37 ± 0.58∗∗∗
Hp. Hex	1000	64.55 ± 0.51∗∗∗	217.93	66.42 ± 0.46∗∗∗	171.05
	500	57.55 ± 0.67∗∗∗		60.53 ± 0.41∗∗∗
	250	51.40 ± 0.44∗∗∗		52.68 ± 0.64∗∗∗
	125	45.67 ± 0.55∗∗∗		47.46 ± 0.47∗∗∗
	62.5	37.33 ± 0.62∗∗		40.51 ± 0.62∗∗∗
Hp. Bt	1000	60.35 ± 0.51∗∗∗	438.39	63.45 ± 0.59∗∗∗	328.34
	500	51.27 ± 0.58∗∗∗		55.49 ± 0.60∗∗∗
	250	43.41 ± 0.55∗∗∗		46.23 ± 0.44∗∗∗
	125	34.40 ± 0.76∗		37.50 ± 0.61∗∗
	62.5	27.24 ± 0.80∗		31.47 ± 0.46∗
Hp. Aq	1000	68.83 ± 1.07∗∗∗	141.2	72.37 ± 0.54∗∗∗	132.27
	500	61.39 ± 0.60∗∗∗		64.00 ± 0.20∗∗∗
	250	56.58 ± 0.56∗∗∗		57.15 ± 0.91∗∗∗
	125	49.29 ± 0.43∗∗∗		51.15 ± 0.61∗∗∗
	62.5	41.37 ± 0.58∗∗∗		40.40 ± 0.68∗∗∗
Celecoxib	1000	84.51 ± 0.30	23.20	—	—
	500	77.84 ± 0.27
	250	73.50 ± 2.26
	125	65.74 ± 0.16
	62.5	61.56 ± 0.28
Montelukast	1000	—	—	87.66 ± 0.45	17.47
	500			81.64 ± 0.42
	250			76.01 ± 1.61
	125			70.46 ± 0.32
	62.5			64.50 ± 0.02

The values are presented as mean ± SEM (n = 5). The asterisk shows that the significance levels in comparison with that of the negative control. Data were analyzed via two-way ANOVA followed by Bonferroni's posttest. ^∗P < 0.05, ^∗∗P < 0.01, and ^∗∗∗P < 0.001.